Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription

Articles published in
Cancer Cell
    April 2024
  1. LIN CJ, Jin X, Ma D, Chen C, et al
    Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
    Cancer Cell. 2024;42:701-719.
    >> Share

    March 2024
  2. BEJARANO L, Kauzlaric A, Lamprou E, Lourenco J, et al
    Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
    Cancer Cell. 2024;42:378-395.
    >> Share

    January 2024
  3. SHIAO SL, Gouin KH 3rd, Ing N, Ho A, et al
    Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
    Cancer Cell. 2024;42:70-84.
    >> Share

  4. GODDARD ET, Linde MH, Srivastava S, Klug G, et al
    Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
    Cancer Cell. 2024;42:119-134.
    >> Share

  5. SHAITELMAN SF, Woodward WA
    Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?
    Cancer Cell. 2024;42:10-12.
    >> Share

    December 2023
  6. SREEKUMAR A, Lu M, Choudhury B, Pan TC, et al
    B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.
    Cancer Cell. 2023 Dec 1:S1535-6108(23)00399-9. doi: 10.1016/j.ccell.2023.
    >> Share

    May 2023
  7. HUTTEN SJ, de Bruijn R, Lutz C, Badoux M, et al
    A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
    Cancer Cell. 2023;41:986-1002.
    >> Share

  8. MAGBANUA MJM, Brown Swigart L, Ahmed Z, Sayaman RW, et al
    Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Cancer Cell. 2023 May 3:S1535-6108(23)00134-4. doi: 10.1016/j.ccell.2023.
    >> Share

    April 2023
  9. MOUSSET A, Lecorgne E, Bourget I, Lopez P, et al
    Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation.
    Cancer Cell. 2023;41:757-775.
    >> Share

    February 2023
  10. VIRASSAMY B, Caramia F, Savas P, Sant S, et al
    Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer.
    Cancer Cell. 2023 Feb 8:S1535-6108(23)00004-1. doi: 10.1016/j.ccell.2023.
    >> Share

    December 2022
  11. BLOMBERG OS, Spagnuolo L, Garner H, Voorwerk L, et al
    IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
    Cancer Cell. 2022 Dec 14:S1535-6108(22)00561-X. doi: 10.1016/j.ccell.2022.
    >> Share

  12. BEHBOD F, Khan SA
    Towards the development of DCIS risk prediction models.
    Cancer Cell. 2022;40:1461-1464.
    >> Share

  13. STRAND SH, Rivero-Gutierrez B, Houlahan KE, Seoane JA, et al
    Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
    Cancer Cell. 2022;40:1521-1536.
    >> Share

  14. GRISARU-TAL S, Munitz A
    T cell-eosinophil crosstalk-A new road for effective immune checkpoint blockade in breast cancer?
    Cancer Cell. 2022 Dec 10:S1535-6108(22)00555-4. doi: 10.1016/j.ccell.2022.
    >> Share

    November 2022
  15. LIU X, Lu Y, Huang J, Xing Y, et al
    CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.
    Cancer Cell. 2022;40:1341-1357.
    >> Share

    June 2022
  16. DENKERT C, Loibl S
    Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes.
    Cancer Cell. 2022;40:592-594.
    >> Share

    May 2022
  17. WOLF DM, Yau C, Wulfkuhle J, Brown-Swigart L, et al
    Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Cancer Cell. 2022 May 25. pii: S1535-6108(22)00216.
    >> Share

    November 2021
  18. KOH SB, Ellisen LW
    Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer.
    Cancer Cell. 2021 Nov 8. pii: S1535-6108(21)00601.
    >> Share

    October 2021
  19. ZHANG Y, Chen H, Mo H, Hu X, et al
    Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.
    Cancer Cell. 2021 Oct 5. pii: S1535-6108(21)00499.
    >> Share

    September 2021
  20. SHIAO SL, Kershaw KM, Limon JJ, You S, et al
    Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy.
    Cancer Cell. 2021;39:1202-1213.
    >> Share

    August 2021
  21. HANKER AB, Brown BP, Meiler J, Marin A, et al
    Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Cancer Cell. 2021;39:1099-1114.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016